After the first two or three Firmagon shots it was recommended that my husband switch to three month Lupron shots for convenience. I had read Firmagon (an antagonist) was a superior drug so we requested he be kept on Firmagon. The injection site discomfort was really only bad the first couple of times and while a monthly shot is inconvenient it's not a big deal. The more I read the more convinced I am we made the right choice.
urotoday.com/video-lectures...
Optimizing ADT in Prostate Cancer Patients - Tom Keane
urotoday.com/video-lectures...
A couple of excerpts from transcript:
Dr. Tom Keane: I think there is, and if there isn't, there certainly should be because I do believe not all LHRH agonists are the same, and certainly an antagonist and an agonist are completely different agents. They have been used as the same agent, but I do not believe they're the same at all. I also don't like when I hear of patients who get started on the antagonist straight away because they get castrated quicker and then converted over to the agonist. Because as CS21 showed, that's going to complete reverse from what the data shows. It was a secondary endpoint. It wasn't a primary endpoint, but once again, there was a difference in how the patients did.
And one other thing that needs to be highlighted is that when, again, this was I believe a study by Albertson where they looked at the death rates for patients in the first year, and there is a distinct difference between the death rates for patients who are on the antagonist as opposed to the agonist. These patients weren't dying of advanced disease. These were newly diagnosed metastatic disease patients who were going on ADT for the first time. As you and I both know, very few patients die within a year of disease.
Dr. Tom Keane: I would say that it's also interesting to see that a lot more medical oncologists now are involved in ADT than there used to be. The people who really did the ADT were the urologists, and a lot of urologists still think of ADT as just render them down to 50. We've got to get the message out there that 50, while it may be acceptable to the FDA, should not be acceptable to us.
And I think the medical oncology people understand that. I think the urology people need to understand that, but we're the people who usually end up giving the ADT first, at least outside of the academic medical centers. It tends to be the private practice urologists, and there's absolutely nothing wrong with that because the urologists have been treating prostate cancer for years, but I do think they need to be aware of the differences between the compounds.